^
Association details:
Biomarker:BTK C481R
Cancer:Chronic Lymphocytic Leukemia
Drug:ibrutinib (BTK inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

BTK AND PLCG2 MUTATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RELAPSING ON IBRUTINIB: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) STUDY BASED ON REAL-WORLD EVIDENCE

Published date:
06/12/2020
Excerpt:
Thirty-one of 59 (53%) R/R pts carried at least 1 hotspot BTK mutation (p.C481S/R/Y) (median VAF 23.3%, range, 1.4%>97.3%) (Table 1). Eight of 31 (26%) mutated pts carried ≥2 hotspot BTK mutations with different VAFs. Seven R/R pts harboring BTK mutation(s) also carried PLCG2 mutation(s) (Table 1)....This study reveals that ~50% of pts relapsing on ibrutinib had a BTK p.C481 mutation by NGS.